Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

NCT06090318 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Advanced Solid Tumor
CDKN2A
NSCLC
Urothelial Carcinoma Bladder
Melanoma
Pancreas Adenocarcinoma
HNSCC
Renal Cell Carcinoma
Mesothelioma
Gastric Cancer

Interventions

DRUG: Milademetan
DRUG: Atezolizumab

Sponsor

Rain Oncology Inc